L-Carnitine vs Tirzepatide
A side-by-side research comparison of L-Carnitine and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | L-Carnitine | Tirzepatide |
|---|---|---|
| Full name | L-Carnitine Injectable | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Supplement / Compounded | FDA Approved |
| Mechanism | Transports long-chain fatty acids across the inner mitochondrial membrane via the carnitine shuttle, enabling beta-oxidation for ATP production. Also reduces oxidative stress and supports cardiac function. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 161.20 Da | 4,814 Da |
| Half-life | ~2-3 hours (IM) | 5 days (120 hours) |
| Bioavailability | ~100% injectable; ~14-18% oral | High (SubQ ~80%) |
| Typical dose | 500-2000 mg | 2.5 mg → titrate up to 15 mg |
| Frequency | 2-5x per week | Once weekly |
| Route | Intramuscular or IV injection | Subcutaneous injection |
L-Carnitine reported benefits
- Enhanced fat oxidation
- Improved energy
- Exercise performance
- Cardiac health
- Recovery support
- Mitochondrial function
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.